Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma

Translational Pediatrics

Volumn 4, Issue 3, 2015, Pages 226-238

  Bassiri, Hamid ^a,b   Benavides, Adriana ^a   Haber, Michelle ^c   Gilmour, Susan K ^d   Norris, Murray D ^c   Hogarty, Michael D ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Experimental therapeutics; Immunotherapy; MYCN; Pre clinical models; Tumor microenvironment

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EFLORNITHINE; MYC PROTEIN; POLYAMINE; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); DRUG EXPOSURE; GENE MUTATION; HUMAN; MEDICAL DECISION MAKING; NEUROBLAST; NEUROBLASTOMA; NONHUMAN; POLYAMINE METABOLISM; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

EID: 84979004833     PISSN: 22244336     EISSN: 22244344     Source Type: Journal    
DOI: 10.3978/j.issn.2224-4336.2015.04.06     Document Type: Article

References (81)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-20.
2. Moreno L, Vaidya SJ, Pinkerton CR, et al. Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience. Pediatr Blood Cancer 2013;60:1135-40.
3. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279-84.
4. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
5. Westermann F, Muth D, Benner A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biology 2008;9:R150.
6. Weiss WA, Aldape K, Bishop JM. Targeted expression of NMYC causes neuroblastoma in transgenic mice. The EMBO Journal 1997;16:2985-95.
7. Koomoa DL, Yco LP, Borsics T, et al. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 2008;68:9825-31.
8. Hogarty MD, Norris MD, Davis K, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008;68:9735-45.
9. Nilsson JA, Keller UB, Baudino TA, et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 2005;7:433-44.
10. Basuroy UK, Gerner EW. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem 2006;139:27-33.
11. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.
12. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-8.
13. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5.
14. Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307:1062-71.
15. Sausen M, Leary RJ, Jones S, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 2013;45:12-7.
16. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
17. Valentijn LJ, Koster J, Haneveld F, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A 2012;109:19190-5.
18. Fredlund E, Ringnér M, Maris JM, et al. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 2008;105:14094-9.
19. O'Connell BC, Cheung AF, Simkevich CP, et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003;278:12563-73.
20. Evageliou NF, Hogarty MD. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma. Clin Cancer Res 2009;15:5956-61.
21. Andersson G, Heby O. Polyamine and nucleic acid concentrations in Ehrlich ascites carcinoma cells and liver of tumor-bearing mice at various stages of tumor growth. J Natl Cancer Inst 1972;48:165-72.
22. Russell D, Snyder SH. Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors. Proc Natl Acad Sci U S A 1968;60:1420-7.
23. Casero RA Jr, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007;6:373-90.
24. Matsufuji S, Matsufuji T, Miyazaki Y, et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 1995;80:51-60.
25. Albeck S, Dym O, Unger T, et al. Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci 2008;17:793-802.
26. Justilien V, Walsh MP, Ali SA, et al. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014;25:139-51.
27. Rounbehler RJ, Li W, Hall MA, et al. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 2009;69:547-53.
28. Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004;101:12664-9.
29. Hackett CS, Hodgson JG, Law ME, et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003;63:5266-73.
30. Moore HC, Wood KM, Jackson MS, et al. Histological profile of tumours from MYCN transgenic mice. J Clin Pathol 2008;61:1098-103.
31. Rasmuson A, Segerstrom L, Nethander M, et al. Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma. PLoS One 2012;7:e51297.
32. Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682-94.
33. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93.
34. Ellis LM, Fidler IJ. Finding the tumor copycat: therapy fails, patients don't. Nat Med 2010;16:974-5.
35. Meyskens FL Jr, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008;1:32-8.
36. Wallick CJ, Gamper I, Thorne M, et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 2005;24:5606-18.
37. Chen Y, Weeks RS, Burns MR, et al. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer 2006;118:2344-9.
38. Boon K, Caron HN, van Asperen R, et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 2001;20:1383-93.
39. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 2010;10:301-9.
40. Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008;456:971-5.
41. Pourdehnad M, Truitt ML, Siddiqi IN, et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A 2013;110:11988-93.
42. Wasylishen AR, Chan-Seng-Yue M, Bros C, et al. MYC phosphorylation at novel regulatory regions suppresses transforming activity. Cancer Res 2013;73:6504-15.
43. Hayes CS, Shicora AC, Keough MP, et al. Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment. Cancer Immunol Res 2014;2:274-85.
44. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64: 5839-49.
45. Hayes CS, Burns MR, Gilmour SK. Polyamine blockade promotes antitumor immunity. Oncoimmunology 2014;3:e27360.
46. Chamaillard L, Quemener V, Havouis R, et al. Polyamine deprivation stimulates natural killer cell activity in cancerous mice. Anticancer Res 1993;13:1027-33.
47. Saini P, Eyler DE, Green R, et al. Hypusine-containing protein eIF5A promotes translation elongation. Nature 2009;459:118-21.
48. Huang Y, Higginson DS, Hester L, et al. Neuronal growth and survival mediated by eIF5A, a polyamine-modified translation initiation factor. Proc Natl Acad Sci U S A 2007;104:4194-9.
49. Landau G, Bercovich Z, Park MH, et al. The role of polyamines in supporting growth of mammalian cells is mediated through their requirement for translation initiation and elongation. J Biol Chem 2010;285:12474-81.
50. Mandal S, Mandal A, Johansson HE, et al. Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. Proc Natl Acad Sci U S A 2013;110:2169-74.
51. Witherspoon M, Chen Q, Kopelovich L, et al. Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine. Cancer Discov 2013;3:1072-81.
52. Bistulfi G, Diegelman P, Foster BA, et al. Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools. FASEB J 2009;23:2888-97.
53. Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol 2010;21:1944-51.
54. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
55. Pistoia V, Morandi F, Bianchi G, et al. Immunosuppressive microenvironment in neuroblastoma. Front Oncol 2013;3:167.
56. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
57. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
58. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
59. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116.
60. Asgharzadeh S, Salo JA, Ji L, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012;30:3525-32.
61. Asgharzadeh S, Pique-Regi R, Sposto R, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006;98:1193-203.
62. Bianchi G, Vuerich M, Pellegatti P, et al. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis 2014;5:e1135.
63. Tilak T, Sherawat S, Agarwala S, et al. Circulating T-regulatory cells in neuroblastoma: a pilot prospective study. Pediatr Hematol Oncol 2014;31:717-22.
64. Croce M, Corrias MV, Orengo AM, et al. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice. Int J Cancer 2010;127:1141-50.
65. Jing W, Yan X, Hallett WH, et al. Depletion of CD25(+) T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood 2011;117:6952-62.
66. Blachier F, Mignon A, Soubrane O. Polyamines inhibit lipopolysaccharide-induced nitric oxide synthase activity in rat liver cytosol. Nitric Oxide 1997;1:268-72.
67. Rodriguez PC, Zea AH, DeSalvo J, et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003;171:1232-9.
68. Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007;204:49-55.
69. Soda K. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res 2011;30:95.
70. Soda K, Kano Y, Nakamura T, et al. Spermine, a natural polyamine, suppresses LFA-1 expression on human lymphocyte. J Immunol 2005;175:237-45.
71. Chamaillard L, Catros-Quemener V, Delcros JG, et al. Polyamine deprivation prevents the development of tumour-induced immune suppression. Br J Cancer 1997;76:365-70.
72. Chamaillard L, Catros-Quemener V, Moulinoux JP. Synergistic activation of macrophage activity by polyamine deprivation and cyclophosphamide. Anticancer Res 1997;17:1059-65.
73. Ferrante A, Maxwell GM, Rencis VO, et al. Inhibition of the respiratory burst of human neutrophils by the polyamine oxidase-polyamine system. Int J Immunopharmacol 1986;8:411-7.
74. Kusmartsev S, Nefedova Y, Yoder D, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004;172:989-99.
75. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008;9:495-502.
76. Jyothi MD, Khar A. Induction of nitric oxide production by natural killer cells: its role in tumor cell death. Nitric Oxide 1999;3:409-18.
77. Kroesen M, Nierkens S, Ansems M, et al. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. Int J Cancer 2014;134:1335-45.
78. Carlson LM, Rasmuson A, Idborg H, et al. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis 2013;34:1081-8.
79. Pless M, Belhadj K, Menssen HD, et al. Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study. Clin Cancer Res 2004;10:1299-305.
80. Siimes M, Seppanen P, Alhonen-Hongisto L, et al. Synergistic action of two polyamine antimetabolites leads to a rapid therapeutic response in childhood leukemia. Int J Cancer 1981;28:567-70.
81. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003;9:981-90.